S6K1 amplification confers innate resistance to CDK4/6 inhibitors through activating c-Myc pathway in patients with estrogen receptor-positive breast cancer.
Molecular Cancer
Mo, Hongnan H; Liu, Xuefeng X; Xue, Yu Y; Chen, Hongyan H; Guo, Shichao S; Li, Zhangfu Z; Wang, Shuang S; Li, Caiming C; Han, Jiashu J; Fu, Ming M; Song, Yongmei Y; Li, Dan D; Ma, Fei F
Molecular landscape of TP53 mutations in breast cancer and their utility for predicting the response to HER-targeted therapy in HER2 amplification-positive and HER2 mutation-positive amplification-negative patients.